
Keywords: ADAM; a disintegrin and metalloprotease; ADEX; aberrantly differentiated endocrine exocrine; ALDH1; aldehyde dehydrogenase 1; CAFs; cancer associated fibroblasts; CDKN2A; cyclin dependent kinase inhibitor 2A; CSC; cancer stem cell; CTC; circulating tumor